Choice of neoadjuvant therapy for rectal cancer: simple chemotherapy or synchronous chemoradiotherapy.
- Author:
Jianxia LI
1
;
Yanhong DENG
2
;
Jianping WANG
3
Author Information
1. Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China. lijx55@mail2.sysu.edu.cn.
2. Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
3. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China. wangjpgz@126.com.
- Publication Type:Journal Article
- MeSH:
Chemoradiotherapy;
China;
Humans;
Neoadjuvant Therapy;
Neoplasm Staging;
Rectal Neoplasms;
therapy;
Treatment Outcome
- From:
Chinese Journal of Gastrointestinal Surgery
2018;21(6):627-631
- CountryChina
- Language:Chinese
-
Abstract:
Rectal cancer is one of the most common malignancies in China. Total mesorectal excision (TME) plus neoadjuvant therapy is the standard treatment for locally advanced rectal cancer. After a development of over 20 years, neoadjuvant synchronous chemoradiotherapy has become the standard treatment and cornerstone of neoadjuvant therapy for rectal cancer. However, radiotherapy does not really increase the overall survival and is associated with long-term impact on the functions of anus, sex, urinary system and fertility, so the application of simple neoadjuvant chemotherapy rises gradually and becomes a potentially better treatment option. This paper elaborates the reason, present research status and future trend of the rising neoadjuvant chemotherapy.
